Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
As at 2022-12-31 |
As at 2021-12-31 |
As at 2020-12-31 |
|---|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | ||||
| Domicile of entity |
Netherlands
|
— | — | — |
| Legal form of entity |
Dutch European public company with limited liability
|
— | — | — |
| Address of entity's registered office |
Laarderhoogtweg 25,
|
— | — | — |
| Description of nature of entity's operations and principal activities |
We are a commercial-stage, global, fully-integrated biopharma company developing
|
— | — | — |
| Name of parent entity |
argenx SE
|
— | — | — |
| Statement of IFRS compliance [text block] |
2
|
— | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | ||||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | ||||
| Current inventories | — |
228,353,000
USD
|
109,076,000
USD
|
25,195,000
USD
|